Experts share the official predictions for RSV surge levels in 2024 and 2025, why the levels change each year, and how to ...

编者按：呼吸道合胞病毒（RSV）作为一种对婴幼儿及免疫功能不全人群构成重大威胁的呼吸道病原体，近年来其疫苗和单克隆抗体的研发取得了诸多进展。在刚结束的2024年美国感染性疾病周（IDWeek 2024）上，多项关于儿童RSV防治的最新研究成果备受瞩目 ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

Besides the flu, other respiratory viruses such as respiratory syncytial virus (RSV) and COVID also tend to peak during the ...

【10 月 23 日电，辉瑞制药 RSV 疫苗获 FDA 批准】 辉瑞制药针对呼吸道合胞体病毒的疫苗已获得美国食品药品管理局（FDA）批准。该疫苗用于 18 - 59 岁年龄段人群接种。

智通财经获悉，美国食品药品监督管理局(FDA)已批准辉瑞公司(PFE.US)的呼吸道合胞病毒(RSV)疫苗Abrysvo用于18至59岁下呼吸道疾病风险增加的人群。这些疾病包括肥胖、糖尿病、慢性阻塞性肺病、心力衰竭、慢性肾病和哮喘。扩大批准是基于3期 ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

纽约 - 辉瑞制药公司（NYSE: ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) ...

The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...